Clinical Trial VICCPED1338


T2009-012 - A Phase I Dose Finding Study of Panobinostat in Children with Refractory Hematologic Malignancies

Principal Investigator(s)

Haydar Frangoul


  • Protocol No. VICCPED1338
  • Open Date: 06/27/2013
  • Staging: Phase I
  • Age Group: Both Child and Adult
  • Scope: National
  • Objective: To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of oral panobinostat in 2 cohorts of patients; those with relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML) dosed three times a week every week and those with relapsed or refractory Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) dosed three times a week every other week.
  • Disease Sites: Pediatrics; Leukemia; Lymphoma; Pediatric Leukemia; Pediatric Lymphoma
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Intrathecal Cytarabine; Panobinostat
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01321346
  • Secondary Protocol No: T2009-012



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.